| Term 
 | Definition 
 
        | Metformin (Glucophage)   Advantages: -low risk of hypoglycemia -weight neutral(possible weight loss) -possible decrease in LDL and TG -possible decrease in CHD   Disadvantages: -metallic taste -may cause gi side effects-decreased by slow titration -Contraindicated in renal suffiency-may cause lactic acidosis |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Drugs: Gyburide (Micronase, Diabeta) Glipezide (Glucotrol, XL) Glimeperide (Amaryl)   A- -generally well tolerated -reduction in CV risks and mortality   D: -weight gain -rash -sun sensitivity -severe hypoglycemia-high risk in elderly and hepatic adn renl disfunction -Glyburide has higher risk of hypoglycemia -glipizide is preferred in elderly and renally impaired |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Repaglinide (Prandin) Nateglinide (Starlix)   A: -accentuated effects around meal ingestion -may be used in renal insufficiency   D: -hypoglycemia and possible weight gain -shorter half life than sulfonylureas ( more frequent admin) |  | 
        |  | 
        
        | Term 
 
        | Thiazolidinediones (Glitazones)     |  | Definition 
 
        | Pioglitazone (Actos) Rosiglitazone (Avandia)   A of Pio: -no hypoglycemia -increase HDL, decrease TG   D of Pio: -weight gain -edema -heart failure -bone fractures   A of Avandia: No hypoglycemia   D of Avandia: -Increase LDL -contraindicated in heart disease |  | 
        |  | 
        
        | Term 
 
        | Alpha glucosadase inhibitor |  | Definition 
 
        | Acarbos (Precose) Glycet (Miglotol)   A: -affective for lowering post-prandial glucose   d:  increase gas production adn gi symptoms -contraindicated in IDD, chronic ulceration, adn partial obstruction |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Exenatide (Byetta) Liraglutide (Victoza)   A: -weight reduction   D: -NVD   *Injectable *Long term safety unknown *black box for thyroid tumors (Victoza) |  | 
        |  | 
        
        | Term 
 
        | Di-peptidyl peptidase 4 inhibitors (DPP-4) |  | Definition 
 
        | Sitagliptin (Januvia) Saxagliptin (Onglyza) Vildagliptin (Tradjenta)   A: -no hypolglycemia -weight neutral   D: -occasional reports of urticaria/ angiodema -cases of pancreatitis seen   *Long term safety unknown |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Pramlintade (Symlin)   A: -used in type 1 and type 2 dm   D: -subcutaneous injection -only as an adjunct to insulin -insulin dosage reduction required upon intiation -never mix Symlin and insulin in same syringe -severe hypoglycemia-especially in type 1 -nausea-titrate gradually -anorexia |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | Rosiglitazone/Glimepiride |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | Lispro (Humulog) Aspart (Novolog) Glulisine (Apidra) |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | Lantus (Glargine) Levomir (Detmir) |  | 
        |  |